What does fisetin do in the body?

Fisetin acts as a potent antioxidant, anti-inflammatory, and senolytic compound by scavenging free radicals, suppressing NF-κB and MAPK inflammatory pathways, and selectively eliminating senescent cells through BCL-2/BCL-XL inhibition. It also activates the Nrf2/ARE pathway to upregulate cytoprotective enzymes like NQO1 and modulates ERK/CREB signaling in neurons to support brain health. These combined mechanisms underlie its investigation for aging, neurodegeneration, and cancer applications.

What is the best food source of fisetin?

Strawberries are the richest known dietary source of fisetin, containing up to approximately 160 μg/g fresh weight, far exceeding other foods. Persimmons, apples, grapes, onions, and cucumbers also contain fisetin but at substantially lower concentrations of roughly 2–10 μg/g. Because these concentrations are so low, achieving the doses used in preclinical research (tens to hundreds of milligrams) through diet alone is essentially not feasible without supplementation.

How much fisetin should I take per day?

No standardized human clinical dose has been established for fisetin because large-scale human trials have not yet been completed. Commercial supplements typically provide 100–500 mg per day, while investigational senolytic protocols explored in early human research have used intermittent high-dose regimens (sometimes exceeding 1,000 mg on consecutive days, once monthly), extrapolated from preclinical data. Individuals should consult a healthcare provider before supplementing, as human safety and efficacy data remain preliminary.

Is fisetin safe to take as a supplement?

Fisetin appears to be well tolerated at moderate supplemental doses based on its rapid phase II metabolism and limited reported adverse effects, but formal human safety trials are lacking. At high concentrations, in vitro studies have identified genotoxic activity—both clastogenic and aneugenic effects—raising theoretical concern for very high or prolonged doses. Pregnancy, lactation, and concurrent use of anticoagulants or immunosuppressants represent situations requiring particular caution given the absence of clinical safety data in these populations.

Does fisetin help with memory and brain health?

Preclinical research in rodent models suggests fisetin supports memory and cognitive function by activating ERK/CREB signaling to enhance synaptic plasticity and long-term potentiation, while also reducing neuroinflammation via NF-κB suppression and protecting neurons from oxidative damage. Animal studies have shown improvements in spatial memory and reductions in age-related neuronal loss with fisetin supplementation. However, human clinical trial data specifically confirming these cognitive benefits are not yet available, so conclusions about efficacy in people remain premature.

Does fisetin interact with chemotherapy drugs or cancer medications?

Fisetin may potentiate certain chemotherapy effects through its topoisomerase II inhibition and PARP cleavage mechanisms, but this interaction requires medical supervision and should be discussed with an oncologist before use. Combining fisetin with DNA-damaging cancer drugs could theoretically enhance efficacy or alter toxicity profiles, so supplementation during active cancer treatment is not recommended without professional guidance.

What is the difference between fisetin and other flavonoids like quercetin or kaempferol?

While fisetin, quercetin, and kaempferol are all flavonoids with antioxidant and anti-inflammatory properties, fisetin is unique for its superior blood-brain barrier penetration and its specific activation of ERK/CREB signaling pathways critical for memory and synaptic plasticity. Fisetin also shows distinct mechanisms in cancer cell lines, particularly through topoisomerase II inhibition, whereas quercetin and kaempferol have different molecular targets and bioavailability profiles.

Who would benefit most from fisetin supplementation—healthy individuals or those with specific conditions?

Fisetin appears most beneficial for individuals concerned with age-related cognitive decline, neuroprotection, and long-term brain health, as well as those exploring complementary approaches to cancer risk reduction, though evidence is strongest in animal models. Healthy individuals seeking preventive neuroprotection may also benefit, but those with existing neurological conditions or cancer diagnoses should consult healthcare providers to determine appropriate use and dosing.

Fisetin

Fisetin (C₁₅H₁₀O₆) is a flavonol polyphenol that exerts antioxidant, senolytic, neuroprotective, and anticancer effects by modulating NF-κB, MAPK, and Bcl-2 family signaling pathways while activating antioxidant-response elements and inhibiting topoisomerase II. Preclinical evidence across multiple cancer cell lines and rodent models demonstrates potent antiproliferative and neuroprotective activity, though human clinical trial data with defined effect sizes remain limited at this time.

Category: Compound Evidence: 1/10 Tier: Preliminary

Origin & History

Fisetin is a naturally occurring flavonol polyphenol distributed widely across the plant kingdom, found in common fruits and vegetables including strawberries, apples, persimmons, grapes, onions, and cucumbers. Strawberries contain the highest reported concentrations, ranging up to approximately 160 μg/g fresh weight, while most other dietary sources contribute far lower amounts (2–10 μg/g). It is not cultivated as an isolated compound but rather obtained as a minor constituent of everyday produce or synthesized/extracted for research and supplementation purposes.

Historical & Cultural Context

Fisetin does not possess a documented history of use as an isolated therapeutic compound in classical herbal medicine traditions such as Ayurveda, Traditional Chinese Medicine, or European phytotherapy, as the tools to identify and characterize individual polyphenols at the molecular level did not exist until modern analytical chemistry. The plant sources containing fisetin—particularly strawberries, onions, and grapes—have long histories of use in folk medicine for anti-inflammatory, digestive, and general tonic purposes, but these benefits were attributed to the whole food or crude extracts rather than any single flavonol constituent. Fisetin was first chemically characterized in the nineteenth century as a yellow dye pigment isolated from Cotinus coggygria (smoketree) heartwood, where it contributes to the tree's traditional use as a natural textile dye across Central Asia and Southern Europe. Its emergence as a biomedical research subject is entirely a twentieth- and twenty-first-century phenomenon, driven by the broader scientific interest in dietary polyphenols following epidemiological associations between fruit and vegetable consumption and reduced chronic disease risk.

Health Benefits

- **Neuroprotection**: Fisetin crosses the blood-brain barrier and activates ERK/CREB signaling to support long-term potentiation and synaptic plasticity; animal studies indicate it reduces oxidative neuronal damage and may attenuate age-related cognitive decline.
- **Anticancer Activity**: Fisetin inhibits topoisomerase II, downregulates securin and TET1, suppresses NF-κB, and induces PARP cleavage and apoptosis in cell lines including HT-29 (colorectal), U266 (myeloma), MDA-MB-231 (breast), and PC-3M-luc-6 (prostate).
- **Senolytic/Anti-Aging Effects**: Fisetin selectively clears senescent cells by modulating BCL-2/BCL-XL survival pathways, reducing the senescence-associated secretory phenotype (SASP) and inflammatory cytokine burden in aged tissues in preclinical models.
- **Antioxidant Defense**: Its o-dihydroxy B-ring structure, 3-hydroxy group, and 2,3-double bond confer exceptional radical-scavenging capacity, outperforming trolox in ferric-reducing antioxidant power (FRAP) assays and activating the antioxidant/electrophile-response element (ARE).
- **Anti-Inflammatory Action**: Fisetin suppresses mast cell activation by blocking PKCα/ROS/ERK1/2 and p38 MAPK pathways, reducing NF-κB nuclear translocation and downstream pro-inflammatory cytokine production including TNF-α and IL-6.
- **Hepatoprotection**: In rodent models, fisetin attenuates hepatic oxidative stress and inflammatory signaling, reducing liver enzyme elevations induced by toxic agents, partly through Nrf2 pathway activation and quinone oxidoreductase (NQO1) induction.
- **Antiviral Potential**: Fisetin has demonstrated in vitro inhibitory activity against several viral targets by interfering with replication machinery and modulating host innate immune signaling, though robust human data are absent.

How It Works

Fisetin exerts its antioxidant effects through its structural features—the o-dihydroxy catechol configuration on the B ring, the 3-OH group, and the C2=C3 double bond—which enable direct radical scavenging, metal chelation, and activation of the ARE/Nrf2 pathway leading to upregulation of NQO1 and other cytoprotective enzymes. Its anticancer mechanism involves inhibition of topoisomerase II (clastogenic at high concentrations, aneugenic at low doses), suppression of NF-κB and MAPK signaling cascades, downregulation of antiapoptotic proteins Bcl-2 and Bcl-XL, modulation of securin and TET1 expression, and induction of intrinsic apoptosis with PARP cleavage across diverse cancer cell lines. Neuroprotective activity is mediated via ERK/CREB pathway activation promoting neurotrophic factor expression, inhibition of neuroinflammatory NF-κB signaling, and reduction of oxidative stress in neuronal tissue. Senolytic activity occurs through selective inhibition of BCL-2 family pro-survival proteins in senescent cells, thereby reducing SASP-driven chronic inflammation that underlies multiple age-related pathologies.

Scientific Research

The current body of evidence for fisetin is predominantly preclinical, consisting of in vitro cell culture experiments (e.g., SGC7901 gastric cancer, GES-1 normal gastric epithelial, HT-29, MDA-MB-231, U266, PC-3M-luc-6 lines) and rodent pharmacokinetic/pharmacodynamic studies, with no large published human randomized controlled trials as of the time of this entry. Pharmacokinetic studies in mice and rats have quantified systemic exposure: intraperitoneal dosing at 223 mg/kg in mice achieved a C_max of 2.5 μg/ml with a rapid half-life of 0.09 hours and a terminal half-life of 3.1 hours, while oral bioavailability is substantially limited by first-pass phase II metabolism. A nanoemulsion formulation improved intraperitoneal bioavailability 24-fold relative to conventional formulations in mice, highlighting the significant delivery challenge for this compound. Ongoing early-phase human trials exploring fisetin's senolytic potential have been registered (notably at Mayo Clinic), but detailed outcomes and effect sizes were not yet publicly available at the time of writing, warranting an honest classification of evidence as preliminary.

Clinical Summary

Clinical evidence for fisetin in humans is currently insufficient to establish standard therapeutic dosing or confirm efficacy endpoints, as the compound's human trial portfolio is in early stages. Preclinical studies consistently demonstrate antiproliferative IC50 values in the low micromolar range across multiple cancer cell lines and cognitive-protective effects in aged murine models, providing biological plausibility. A small pilot human study exploring fisetin's senolytic effects in older adults with metabolic dysfunction was initiated by Mayo Clinic researchers, examining reductions in circulating senescent cell burden and SASP markers, but full results with effect sizes were not published in the available literature at this time. Confidence in clinical recommendations remains low pending adequately powered phase II/III RCTs; the compound's preclinical profile justifies continued investigation but caution against therapeutic claims in human populations.

Nutritional Profile

Fisetin is a pure polyphenolic flavonol compound (C₁₅H₁₀O₆, MW 286.24 g/mol) and does not contribute meaningfully to macronutrient or general micronutrient intake when consumed at dietary concentrations. At the molecular level, its four hydroxyl groups (at positions 3, 3′, 4′, and 7) confer its characteristic antioxidant and bioactive properties; it lacks methoxy substitutions that characterize some related flavonols like quercetin. Dietary sources provide fisetin alongside other flavonols (quercetin, kaempferol), anthocyanins, vitamin C, and dietary fiber, creating a complex polyphenol matrix that may influence fisetin's absorption and bioactivity. Bioavailability from whole foods is inherently low due to food matrix binding, intestinal phase II metabolism (rapid sulfation and glucuronidation producing sulfate and glucuronide conjugates), and poor aqueous solubility; sulfate/glucuronide metabolites in plasma are present at 2.2-fold greater AUC than glucuronides alone after oral dosing and retain measurable antioxidant activity.

Preparation & Dosage

- **Standardized Capsules/Tablets**: Most commercial supplements provide 100–500 mg of fisetin per dose, often standardized to ≥98% fisetin purity by HPLC; no clinically validated human dose has been established.
- **Senolytic Protocols (Investigational)**: Preclinical and early clinical explorations have used intermittent high-dose regimens (e.g., 2–3 consecutive days per month at doses extrapolated to 20 mg/kg in humans), though these remain experimental.
- **Animal Reference Doses**: Oral 50 mg/kg and IV 10 mg/kg in rats; intraperitoneal 223 mg/kg in mice—these cannot be directly extrapolated to human supplemental doses.
- **Nanoemulsion/Lipid-Based Forms**: Under research investigation to address poor aqueous solubility (~1 μg/ml in water); these formulations showed 24-fold improved bioavailability in mice and may represent future delivery innovations.
- **Dietary Intake**: Natural dietary exposure from strawberries (up to 160 μg/g) and other produce yields only microgram-level daily intake, far below doses used in preclinical studies.
- **Timing Notes**: Fat co-administration may modestly improve absorption given fisetin's lipophilic character; rapid phase II metabolism suggests multiple smaller daily doses may maintain steadier plasma exposure than single large doses.

Synergy & Pairings

Fisetin and quercetin are frequently co-investigated as senolytic combinations, as both flavonols target BCL-2/BCL-XL survival pathways in senescent cells through overlapping but distinct binding interactions, with preclinical data suggesting additive clearance of p16-positive senescent cells when combined at sub-maximal individual doses. Pairing fisetin with piperine (from black pepper) or lipid-based delivery matrices is proposed to enhance oral bioavailability by inhibiting intestinal sulfotransferases and improving micellar solubilization, respectively, thereby increasing the fraction of intact fisetin reaching systemic circulation. Fisetin combined with resveratrol has been explored in neurodegeneration models, with complementary Sirt1 activation (resveratrol) and NF-κB/MAPK suppression (fisetin) providing broader neuroprotective coverage than either compound alone in rodent studies.

Safety & Interactions

At high concentrations, fisetin exhibits genotoxic activity in vitro, with both clastogenic effects (chromosomal breaks at elevated doses) and aneugenic effects (spindle interference at lower doses), raising theoretical concern for high-dose supplementation, though the physiological relevance of these findings for typical oral supplemental doses in humans remains to be clarified. No well-characterized clinical drug interaction data exist for fisetin in humans; given its role as a substrate and potential modulator of phase II metabolic enzymes (sulfotransferases and UGTs) and possible effects on CYP450 activity based on structural analogy with quercetin, caution is warranted with concurrent use of anticoagulants, immunosuppressants, and drugs with narrow therapeutic windows. Contraindications have not been formally established, but pregnancy and lactation represent standard precautionary contraindications given the complete absence of human safety data in these populations. Maximum safe doses for humans have not been determined; rapid phase II metabolism may limit systemic exposure and reduce toxicity risk at moderate supplement doses (100–500 mg/day), but genotoxicity signals justify conservative dosing and avoidance of prolonged high-dose use until human safety trials are completed.